The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004
Abstract
Objective . To analyze the relative influence of factors in decisions for public insurance coverage of new drugs in Australia. Data Sources . Evidence presented at meetings of the Australian Pharmaceutical Benefits Advisory Committee (PBAC) that makes recommendations on coverage of drugs under Pharmaceutical Benefits Scheme. Study Selection . All major submissions to the PBAC between February 1994 and December 2004 (n = 858) if one of the outcomes measured was life year gained (n= 138) or quality-adjusted life years (QALYs) gained (n= 116). Results . Clinical significance, cost-effectiveness, cost to government, and severity of disease were significant influences on decisions. Compared to the average submission, clinical significance increased the probability of recommending coverage by 0.21 (95% confidence interval [CI] 0.02 to 0.40), whereas a drug in a life-threatening condition had an increased probability of being recommended for coverage of 0.38 (0.06 to 0.69). An increase in $A10,000 from a mean incremental cost per QALY of $A46,400 reduced the probability of listing by 0.06 (95% CI 0.04 to 0.1). Conclusions . The PBAC provides an example of the long-term stability and coherence of evidence-based coverage and pricing decisions for drugs that weighs up the evidence on clinical effectiveness, clinical need, and value for money. There is no evidence of a fixed public threshold value of life years or QALYs, but willingness to pay is clearly related to the characteristics of the clinical condition, perceived confidence in the evidence of effectiveness and its relevance, as well as total cost to government.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A REVIEW OF GOODNESS OF FIT STATISTICS FOR USE IN THE DEVELOPMENT OF LOGISTIC REGRESSION MODELS1
LEMESHOW, S., & HOSMER, D. W. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113284 · Cited by 1,947
Cited by
Alonso-Coello, P., Schünemann, H. J., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Rada, G., Rosenbaum, S., et al. (2016) · BMJ · doi:10.1136/bmj.i2016 · Cited by 1,317
Cost–effectiveness thresholds: pros and cons
Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164418 · Cited by 783
Self-citationBennell, K. L., Ahamed, Y., Jull, G., Bryant, C., Hunt, M. A., Forbes, A. B., Kasza, J., Akram, M., Metcalf, B., Harris, A., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22744 · Cited by 406
Self-citationClement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., & Manns, B. J. (2009) · JAMA · doi:10.1001/jama.2009.1409 · Cited by 343
Self-citationLee, Y. Y., Barendregt, J. J., Stockings, E. A., Ferrari, A. J., Whiteford, H. A., Patton, G. A., & Mihalopoulos, C. (2017) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000469 · Cited by 85
Metadata
- Authors
- Harris, A. H., Hill, S. R., Chin, G., Li, J. J., & Walkom, E.
- Venue
- Medical Decision Making
- Publisher
- SAGE Publications
- Published
- 2008-06-30
- Volume
- 28
- Issue
- 5
- Pages
- 713-722
- ISSN
- 0272-989X (ISSN-L)
- 1552-681X
- OpenAlex
- W2117042820
- Cited by
- 217
- References
- 1
- FWCI
- 19.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004. https://app.cochat.ai/papers/10.1177/0272989x08315247
- The paper
- Harris, A. H., Hill, S. R., Chin, G., Li, J. J., & Walkom, E. (2008). The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004. Medical Decision Making. https://doi.org/10.1177/0272989x08315247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.